All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-06-14T07:56:57.000Z

The FDA grants OXi4503 Fast Track Designation for the treatment of AML

Jun 14, 2017
Share:

Bookmark this article

On 7th June 2017, the U.S. Food and Drug Administration (FDA) granted a Fast Track Designation to OXi4503 for the treatment of patients with Acute Myeloid Leukemia (AML).1

 OXi4503 (combretastatin A1 di-phosphate) is a dual mechanism vascular disrupting agent that has been shown to destroy tumor vasculature, leading to extensive tumor cell death and necrosis.  Additionally, OXi4503 can undergo oxidative stress to quinone intermediate to produce cytotoxicity against tumor cells. Preclinical studies of OXi4503 in AML have shown that this agent could induce phenotypic and molecular remissions in subtypes of AML including Fms Like Tyrosine Kinase 3 (FLT3) mutated AML through multiple mechanisms including vascular disruption and apoptosis. 2

 OXi4503 is currently being explored in a phase I/II study (NCT02576301) in patients with Relapsed or Refractory (R/R) AML. The aim of the phase 1 portion of this study is to investigate the maximum tolerated dose of OXi4503 monotherapy and in combination with intermediate-dose cytarabine in R/R AML patients. The aim of the phase II portion of the study is to investigate the overall response rate of OXi4503 in combination with intermediate-dose cytarabine in R/R AML patients after treatment failure of up to 1 prior chemotherapy regimen.

  1. GlobeNewswire: Mateon Therapeutics Receives FDA Fast Track Designation for OXi4503 in Patients with Acute Myeloid Leukemia. 2017 Jun 7.https://globenewswire.com/news-release/2017/06/07/1009281/0/en/Mateon-Therapeutics-Receives-FDA-Fast-Track-Designation-for-OXi4503-in-Patients-with-Acute-Myeloid-Leukemia.html. [Accessed 2017 Jun 8].
  2. Madlambayan G.J. et al. Leukemia regression by vascular disruption and antiangiogenic therapy. Blood. 2010 Sep 2; 116(9): 1539–1547. DOI: 10.1182/blood-2009-06-230474. Epub 2010 May 14.
More about...

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 6 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox